Value proposition

Redefining the future of drug development with a non-conventional biopharmaceutical model

Landmark BioVentures AG (LBV), founded in 2021 and headquartered in Basel, Switzerland, is an integrated and agile biotech hub-and-spoke company. LBV takes a unique model focused on lean operations, smart resource allocation and a diversified yet complementary pipeline of 10 first-in-class therapeutics, each being developed within a nexus of seven startups built from the ground up. Led by a seasoned multidisciplinary team of drug developers, entrepreneurs and deal makers, LBV harnesses its specialized and industry-relevant drug development expertise and opportunistic and creative deal-making in resource-constrained environments to streamline drug development by starting with the end in mind.

drug development , biotech, oncology, immuno-oncology, ophthalmology, immunology, pathobiology, inflammation, and business development